Carson City, Nevada, January 29, 2018, Cell MedX Corp. (OTCQB: CMXC; 9CX:MUN), (“Cell MedX” or the “Company”), announces that it has been assigned a Legal Entity Identifier number 967600RJ7LKTH79OWE67.
About the Legal Entity Identifier Number (“LEI”)
The European Union has adopted regulations that require use of the LEI as a barcode equivalent aimed at pinpointing systemic risks. The LEI is a 20-digit alphanumeric code that is an internationally standardized and globally valid identifier for financial market participants. Its purpose is to clearly and unequivocally identify contracting parties, such as other companies, banks and investment funds. It is used to comply with a variety of financial reporting requirements in Europe, including trading, clearing, settlement, custody, collateral and liquidity management, market data and indices. The Deutsche Bӧrse Group has stated that “the LEI will clearly assist the regulatory authorities in monitoring and analyzing threats to the stability of the financial markets and it can also be utilized by counterparties for risk management purposes”.
(See http://deutsche-boerse.com/dbg-en/regulation/regulatorytopics/legal-entity-identifier).
Cell MedX meets the requirement that all companies on German Stock Exchanges have an LEI number by January 3, 2018. The Company is listed on the Munich Stock Exchange under the symbol 9CX.
Dr. Terrance Owen, CEO, stated, “Adhering to the requirements of the stock exchanges in Germany is important to Cell MedX in order to provide liquidity for European shareholders, especially as we introduce eBalance technology and become better known in the investment community”.
About Cell MedX Corp.
Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com
On behalf of the Board of Directors of Cell MedX Corp.
Terrance Owen
CEO & Director
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA or Health Canada, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
SOURCE:
Cell MedX Corp.
For further information visit: www.cellmedx.com.
Or phone: 1-844-238-2692